Core Viewpoint - The stock of Jimin Health Management Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative closing price deviation exceeding 20% over three consecutive trading days, indicating potential market risks [2][5][9]. Group 1: Stock Trading Abnormalities - The company's stock price increased by a cumulative deviation of 75.32% over the past 30 trading days, suggesting significant volatility that diverges from the company's operational performance [2][9]. - The stock experienced a cumulative closing price deviation of over 20% on September 8, 9, and 10, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [5][9]. Group 2: Company Verification and Response - The company conducted a self-examination and confirmed that there have been no significant changes in its main business or external operating environment, and no undisclosed major events exist [6][7]. - The controlling shareholder disclosed a share reduction plan on September 5, 2025, but no other major transactions or restructuring activities were reported [3][6]. Group 3: Financial Performance - For the first half of 2025, the company reported a net loss of 52.70 million yuan, a decline compared to the same period last year [9].

关于济民健康管理股份有限公司 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025年 9 月 10 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权,为公司实际控 制人。 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 双鸽集团有限公司 2×年9月/0日 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 本家族全体成员于 2025年9月10 ...

●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司控股股东于 2025 年 9 月 5 日披露了减持股份计划。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 证券代码：603222 证券简称：济民健康 公告编号：2025-045 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●公司股票交易于 2025 年 9 月 8 日、9 月 9 日、9 月 10 日连续三个交易日内 收盘价格涨幅偏离值累计超过 20%，属于《上海证券交易所交易规则》规定的股票 交易异常波动情形。公司股价近 30 个交易日涨幅偏离值累计达 75.32%，剔除大盘 和板块整体因素后的实际涨跌幅波动较大，存在异常交易情形，公司股价走势与 经营业绩趋势相偏离，敬请广大投资者注意二级市场交易风险，理性决策，审慎 投资。 （一）经公司自查，公司主营业务未发生重大变化，内外部经营环境未发生 ...

Group 1 - The stock of Jimin Health has experienced a significant increase, with 6 limit-up days in the last 10 trading days, resulting in a cumulative increase of 39.32% and a turnover rate of 177.70% [2] - As of 9:52 AM, the stock's trading volume reached 65.8 million shares, with a transaction amount of 813 million yuan, and a turnover rate of 12.53% [2] - The total market capitalization of Jimin Health in the A-share market is currently 6.679 billion yuan [2] Group 2 - The latest margin trading data shows that as of September 8, the margin balance for the stock is 167 million yuan, with a decrease of 31.4 million yuan from the previous trading day, representing a decline of 15.83% [2] - Over the past 10 days, the margin balance has decreased by a total of 108 million yuan, reflecting a decline of 39.16% [2] - The stock has appeared on the Dragon and Tiger list three times due to significant price deviations, with a net buying amount of 16.35 million yuan from the leading brokerage firms [2] Group 3 - The company's semi-annual report released on August 21 indicates that total operating revenue for the first half of the year was 366 million yuan, a year-on-year decrease of 21.30% [2] - The net profit for the same period was -53 million yuan, representing a year-on-year decline of 307.10% [2]

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]

Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]

Summary of Key Points Core Viewpoint - Jimin Health has experienced significant stock price fluctuations, achieving five trading halts within nine trading days, resulting in a cumulative increase of 26.62% and a turnover rate of 156.83% [2]. Trading Performance - As of 9:38 AM, the stock recorded a trading volume of 25.996 million shares and a transaction amount of 291 million yuan, with a turnover rate of 4.95% [2]. - The total market capitalization of Jimin Health reached 6.07 billion yuan [2]. Margin Trading Data - The latest margin trading balance as of September 5 is 199 million yuan, with a financing balance of 198 million yuan, reflecting an increase of 29.105 million yuan or 17.19% compared to the previous trading day. However, over the past nine days, the cumulative decrease is 76.109 million yuan, representing a decline of 27.72% [2]. Stock Performance Metrics - The stock has been listed on the Dragon and Tiger list three times due to significant price deviations, with a cumulative deviation of 20% over three trading days, a daily drop deviation of 7%, and a daily fluctuation of 15% [2]. - The net buying from leading brokerage firms amounted to 16.3546 million yuan [2]. Financial Results - According to the semi-annual report released on August 21, the company achieved total operating revenue of 366 million yuan in the first half of the year, a year-on-year decrease of 21.30%. The net profit was -53 million yuan, reflecting a year-on-year decline of 307.10% [2].

Group 1 - Jimin Health (603222) experienced a decline of 8.77% on the trading day, with a turnover rate of 17.07% and a transaction amount of 949.7 million yuan, showing a fluctuation of 7.12% [1] - The stock was listed on the Shanghai Stock Exchange's watch list due to a daily price deviation of -10.01%, with a total net sell of 76.36 million yuan from brokerage seats [1] - Over the past six months, the stock has appeared on the watch list 11 times, with an average price increase of 1.50% the day after being listed and an average increase of 5.91% over the following five days [1] Group 2 - As of September 4, the latest margin trading balance for the stock was 16.9 million yuan, with a financing balance of 16.9 million yuan and a securities lending balance of 91,000 yuan [2] - In the past five days, the financing balance decreased by 73.94 million yuan, representing a decline of 30.40%, while the securities lending balance increased by 7,890 yuan, showing a growth of 649.41% [2] - The company reported a revenue of 366 million yuan for the first half of the year, a year-on-year decrease of 21.30%, and a net profit of -52.7 million yuan [2] Group 3 - On September 5, the top five buying brokerage seats included Guosen Securities (Shenzhen) with a purchase amount of 10.28 million yuan, while the top selling brokerage was Guotai Junan Securities with a selling amount of 41.93 million yuan [3] - The second and third largest buying brokerage seats were Dongguan Securities (Nanjing) and Guosen Securities (Zhejiang), with purchase amounts of 9.59 million yuan and 9.50 million yuan respectively [3] - The second and third largest selling brokerage seats were Zhongtai Securities (Hubei) and Zhongtai Securities (Changzhou), with selling amounts of 25.79 million yuan and 19.53 million yuan respectively [3]

Core Viewpoint - Jimin Health (603222) experienced a significant decline of 8.77% in its stock price, with a trading volume of 9.47 billion yuan and a turnover rate of 17.07% on the day of the report [1][2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's watch list due to a daily price deviation of -10.01%, with a total net sell of 76.36 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction volume of 171 million yuan, with buying amounting to 47.21 million yuan and selling at 124 million yuan, resulting in a net sell of 76.36 million yuan [2]. - The largest buying brokerage was Guosen Securities, Shenzhen, with a purchase amount of 10.28 million yuan, while the largest selling brokerage was Guotai Junan Securities, with a sell amount of 41.93 million yuan [2]. Stock Performance and Fund Flow - Over the past six months, the stock has appeared on the watch list 11 times, with an average price increase of 1.50% the day after being listed and an average increase of 5.91% in the following five days [3]. - On the day of the report, the stock saw a net outflow of 9.61 million yuan in principal funds, with a significant outflow of 10.44 million yuan from large orders, while smaller orders saw a net inflow of 835,000 yuan [3]. - In the past five days, the total net outflow of principal funds reached 69.01 million yuan [3]. Financial Performance - According to the semi-annual report released on August 21, the company achieved a revenue of 366 million yuan in the first half of the year, representing a year-on-year decline of 21.30%, and reported a net loss of 52.70 million yuan [4].

Summary of Key Points Core Viewpoint - Jimin Health (603222.SH) announced a share reduction plan by its major shareholder, Shuangge Group, which holds 127,983,520 shares, accounting for 24.37% of the company's total shares. The reduction is due to Shuangge Group's funding needs and will involve selling up to 15,752,718 shares, or 3% of the total shares, over a three-month period starting 15 trading days after the announcement [1][2]. Group 1: Share Reduction Details - Shuangge Group plans to reduce its holdings through two methods: a maximum of 5,250,906 shares via centralized bidding and 10,501,812 shares through block trading [2]. - The reduction period is set from September 29, 2025, to December 26, 2025 [2]. - Based on the closing price of 11.52 yuan on September 4, the total cash to be raised from the reduction is approximately 181 million yuan [1]. Group 2: Shareholder Background - Shuangge Group is the controlling shareholder of Jimin Health, with actual control held by the Li Xianyu family, which owns 77,277,020 shares, representing 14.72% of the total shares [2]. - The shares held by Shuangge Group were acquired prior to the company's IPO and through capital reserve conversion [2]. Group 3: Historical Share Reductions - Since the first reduction on July 9, 2020, Shuangge Group has cumulatively reduced its holdings by 20,250,000 shares, realizing approximately 36.9 million yuan in cash [3]. - The historical data shows various reduction transactions with different average prices and amounts, totaling 20,250,000 shares and 368.58 million yuan in cash [4].